Document text
Principal Investigator: Kathleen M Hill Gallant
Organization: UNIVERSITY OF MINNESOTA
Fiscal Year: 2024
Award: $665,821
Funding agency: National Institute of Diabetes and Digestive and Kidney Diseases
PROJECT SUMMARY/ABSTRACT
Chronic kidney disease (CKD) is highly prevalent, affecting approximately 37 million U.S. adults. CKD-
mineral and bone disorder (CKD-MBD) is a common comorbidity of CKD that results in increased risk of
cardiovascular and bone disease and associated morbidity and mortality. Abnormal phosphorus (P) metabolism
is central to the development of CKD-MBD and is intimately linked with calcium (Ca) metabolism. Incomplete
understanding of the underlying physiology of Ca and P in CKD and in response to treatments is a major
knowledge gap that hinders research and clinical progress in CKD-MBD. P and Ca physiology is complex and
involves interacting effects of three regulatory hormones, calcitriol, parathyroid hormone, and fibroblast growth
factor-23, on a multi-tissue axis of intestine, kidney, and bone. Despite the complexity, most human research
has relied on serum and urine Ca and P measures to infer aspects of whole-body physiology. Yet, prior work
has shown that serum and urine Ca and P are not reliable markers of whole-body balance or intestinal absorption
in CKD. Formal metabolic balance studies combined with isotope tracers can reveal the underlying whole-body
Ca and P physiology and, notably, can distinguish intestinal absorption from bone resorption and formation. This
project seeks to fill this knowledge gap through two specific aims. Aim 1 will determine the effects of dietary P
restriction on P and Ca intestinal absorption, whole-body balance, and kinetics in adults with moderate CKD.
Aim 2 will determine the effects of calcitriol, a key P and Ca regulatory hormone, on P and Ca intestinal
absorption, whole-body balance, and kinetics in adults with moderate CKD. Each aim will be addressed in a
clinical study using a two-phase randomized cross-over design with controlled feeding and metabolic balance
and kinetics methods in adults with moderate-stage CKD. In Study 1 (Aim 1), subjects will be randomly assigned
to a cross-over order of low and high diet P, achieved through manipulation of P source based on current
understanding that inorganic P sources have much higher bioaccessibility compared with P found naturally in
plant and animal foods, as recommended by current guidelines. In the second study (Aim 2), subjects will be
randomly assigned to a cross-over order of calcitriol and identical placebo. Each study will consist of a 1-week
run-in period on the controlled diet/intervention, 1-week full metabolic balance period with complete urine and
stool collections and oral and intravenous administration of P and Ca isotopes for kinetic modeling to determine
components of P and Ca metabolism including: intestinal absorption, renal clearance, and movement to and
from bone, with kinetic measures continuing during a third week. After a washout period, subjects will cross-over
to the second intervention period. The long-term objective of this project is to advance foundational knowledge
of whole-body P and Ca physiology in CKD that will contribute to progress in translational and clinical research
with the goal of reducing morbidity and mortality associated with CKD-MBD. This relates to the mission of the
NIDDK to support research aimed at improving the health and quality of life of patients with kidney disease.
Terms: <21+ years old><Address><Adult><Adult Human><Adverse effects><Affect><Animal Feed><Area><Autoregulation><Blood Serum><Body Tissues><Bone Diseases><Bone Formation><Bone Mineralization><Bone Resorption><Calcitriol><Calcium><Calcium Isotopes><Cessation of life><Chronic Kidney Failure><Chronic Renal Disease><Chronic Renal Failure><Clinical><Clinical Research><Clinical Study><Clinical Trials><Collection><Common Rat Strains><Complex><Cross-Over Designs><Crossover Design><Data><Death><Development><Diet><Dietary Phosphorus><Disease><Disorder><Endocrine Gland Secretion><Equilibrium><Event><Excretory function><FGF23 gene product><Feces><Fracture><Future><Goals><Guidelines><Health><Homeostasis><Hormonal><Hormones><Human><Hypercalcemia><Hyperparathyroidism><Intake><Intermediary Metabolism><Intervention><Intervention Strategies><Intestinal><Intestinal Absorption><Intestines><Isotopes><Kidney><Kidney Diseases><Kidney Urinary System><Kinetics><Knowledge><Link><Measurement><Measures><Metabolic><Metabolic Processes><Metabolism><Methods><Minerals><Mission><Modeling><Modern Man><Morbidity><Morbidity - disease rate><Movement><NIDDK><National Institute of Diabetes and Digestive and Kidney Diseases><Nephropathy><Oral Administration><Oral Drug Administration><Organism-Level Process><Organismal Process><Osteoclastic Bone Loss><Osteogenesis><Outcome><PTH gene><Parathyrin><Parathyroid Hormone><Patients><Pharmaceutical Agent><Pharmaceuticals><Pharmacologic Substance><Pharmacological Substance><Phase><Phosphorous><Phosphorus><Physiologic><Physiologic Processes><Physiologic calcification><Physiological><Physiological Calcification><Physiological Homeostasis><Physiological Processes><Physiology><Placebos><Plants><Prevention><QOL><Quality of life><Randomized><Rat><Rats Mammals><Rattus><Recommendation><Renal Disease><Renal clearance function><Reporting><Research><Research Support><Risk><Role><Running><Serum><Sham Treatment><Source><Therapeutic Hormone><Tissues><Tracer><Translational Research><Translational Science><Urine><VIT D><Vitamin D><Vitamin D Analog><Work><absorption><adulthood><analog><animal food><balance><balance function><body movement><bone><bone disorder><bone fracture><bone fragility><bone tissue formation><bone turnover><bowel><calcium absorption><calcium metabolism><cardiovascular disease risk><cardiovascular disorder risk><cardiovascular risk><cardiovascular risk factor><chronic kidney disease><co-morbid><co-morbidity><comorbidity><design><designing><developmental><dietary><diets><excretion><experience><feeding><fibroblast growth factor 23><fragile bone><fragility fracture><gastrointestinal absorption><improved><in vivo><innovate><innovation><innovative><interventional strategy><intraoral drug delivery><intravenous administration><kidney disorder><kinetic model><mortality><parathormone><pharmaceutical><prevent><preventing><randomisation><randomization><randomly assigned><renal><renal calcium><renal clearance><renal disorder><response><response to therapy><response to treatment><sham therapy><social role><stool><therapeutic response><therapy response><translation research><translational investigation><treatment response><treatment responsiveness>